Cargando…
Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial
BACKGROUND: Cognitive impairments are well-established features of psychotic disorders and are present when individuals are at ultra-high risk for psychosis. However, few interventions target cognitive functioning in this population. AIMS: To investigate whether omega-3 polyunsaturated fatty acid (n...
Autores principales: | Cheng, Nicholas, McLaverty, Alison, Nelson, Barnaby, Markulev, Connie, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y. H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Street, Rebekah, Thompson, Andrew, Yuen, Hok Pan, Hester, Robert, Yung, Alison Ruth, McGorry, Patrick D., Allott, Kelly, Amminger, G. Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534907/ https://www.ncbi.nlm.nih.gov/pubmed/36073014 http://dx.doi.org/10.1192/bjo.2022.572 |
Ejemplares similares
-
T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY
por: Berger, Maximus, et al.
Publicado: (2018) -
T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL
por: Schlögelhofer, Monika, et al.
Publicado: (2020) -
T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION
por: Schlögelhofer, Monika, et al.
Publicado: (2018) -
O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL
por: Allott, Kelly, et al.
Publicado: (2018) -
F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS
por: Paul Amminger, G, et al.
Publicado: (2018)